Myelofibrosis
from OrphaChat — a Rare Disease Podcast Hosted by RCH
These sources provide a comprehensive analysis of primary myelofibrosis, focusing on the evolution of prognostic toolsand therapeutic interventions. Researchers highlight the clinical utility of scoring systems like DIPSS-plus and MIPSS70, which integrate genetic mutations and cytogenetic data to predict patient survival more accurately. The documents examine the impact of driver mutations, specifically JAK2, CALR, and MPL, alongside the influence of VEGFA polymorphisms on disease severity. Treatment discussions cover JAK inhibitors like ruxolitinib and momelotinib, as well as the emergence of imetelstat for managing transfusion dependence. Furthermore, the texts outline diagnostic criteria and management strategies for related complications, such as splenomegaly and portal hypertension. Overall, the collection reflects a shift towards personalised medicine in managing this complex myeloid malignancy.
Embed this episode
No transcript yet.